Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print]. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii:…
DetailsHIF-1α and rapamycin act as genosuppressant in multiple myeloma cells upon genotoxic stress. Coudre C et al. Cell Cycle. 2016 Jun 24:0. [Epub ahead of print]. CA-125 secreting IgG kappa Multiple Myeloma (MM). Boota M et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print]. To B(ortezomib) or Not to B: The Stroma’s the Thing. Krem MM et al. J Pathol. 2016 Jun 24.…
DetailsMultiple myeloma: practice patterns across Europe. Raab MS et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14193. [Epub ahead of print]. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Prasad V et al. Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028. Pomalidomide in the management of…
DetailsCitrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. Marn Pernat A et al. Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432. Effective Removal of x03BA;-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings. Jayaballa M et al. Blood Purif. 2016 Jun 8;42(2):158-159. [Epub ahead of print]. Thirteen treatment…
DetailsUsual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. Chalayer E et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24454. [Epub ahead of print]. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Karrasch…
DetailsUpdated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Hulin C et al.J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print]. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following…
Details
This NICE guidance covers medical and NHS service recommendations for children and adults who have received a diagnosis of a haematological cancer.
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Terpos E et al. Blood Cancer J. 2016 May 27;6:e428. doi: 10.1038/bcj.2016.37. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Bhatti S et al. Eur Heart J Cardiovasc Imaging. 2016 May 25. pii: jew101. [Epub…
Details